Anavex Life Sciences Corp (AVXL)

[Bourbon_on_my_cornflakes]

Interesting comment on Precision Medicine. Another stock of mine is working with AMGN on precision cancer therapies. With the now low cost to sequence and analyze DNA, the ability to chart out the genetics of "superresponders" would enable AVXL to load p3 with the people most likely to respond to 273, substantially increasing the rate of response and making FDA approval a slam dunk. I would expect that is what is occurring, that we are not merely pouring over the p2 data, but performing additional genetic testing to find out why certain people are superresponding, which would account for the time it is taking. Think of it as screening for height, shooting ability and dribbling skill while assembling a basketball team...we are likely to do much better in p3 than a randomly assembled trial base. Missling as Knute Rockne or Casey Stengel or Chuck Knoll...we will see.